Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PPMX T002

Next Previous
X
Search
Drug Profile

PPMX T002

Alternative Names: 225Ac/177Lu-Cadherin3; 225Ac/177Lu-Cadherin3 - Peptidream/Perseus Proteomics; PPMX-T002

Latest Information Update: 25 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Perseus Proteomics
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 24 Jul 2024 Perseus Proteomics plans a phase II trial for Solid tumours (Perseus Proteomics pipeline, July 2024)
  • 23 Jul 2024 Preclinical trials in Solid tumours in Japan (Parenteral) prior to July 2024
  • 26 Jul 2023 PPMX T002 is available for licensing as of 26 Jul 2023 (Perseus proteomics pipeline, July 2023) https://www.ppmx.com/en/rd/technologies.html#tech1

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top